Description

BSE announces the listing of 5,000 debt securities issued by Nuvama Wealth and Investment Limited on private placement basis with 9.20% interest rate and maturity date of December 20, 2027.

Summary

BSE has listed new debt securities of Nuvama Wealth and Investment Limited issued on private placement basis, effective October 14, 2025. The securities carry a 9.20% annual interest rate, CARE AA/Stable rating, and mature on December 20, 2027. A total of 5,000 securities with face value of Rs. 100,000 each have been listed under ISIN INE523L07AM2.

Key Points

  • Quantity listed: 5,000 securities
  • Scrip Code: 976911
  • Scrip ID: 920NWIL27
  • ISIN: INE523L07AM2 (further listings under same ISIN)
  • Face Value: Rs. 100,000 per security
  • Issue Price: Rs. 102,564.1150
  • Market Lot: 1
  • Credit Rating: CARE AA/Stable
  • Interest Rate: 9.20% per annum (paid annually)
  • Trading only in dematerialized form
  • Tick size: 1 paise
  • No put/call options

Regulatory Changes

No regulatory changes introduced. This is a routine listing notification.

Compliance Requirements

  • Trading members must trade these securities only in dematerialized form under the specified ISIN
  • Members should refer to the Placement Memorandum available at BSE’s debt memorandum section for complete details
  • For clarifications, trading members should contact BSE debt department at 22728352/8597/8995/5753/8915

Important Dates

  • Date of Allotment: October 13, 2025
  • Listing Date: October 14, 2025
  • Interest Payment: Annually
  • Redemption Date: December 20, 2027

Impact Assessment

This is a routine debt security listing with minimal market impact. The listing expands Nuvama Wealth and Investment Limited’s debt capital base through private placement. The securities are rated CARE AA/Stable, indicating high creditworthiness. Impact is limited to institutional investors participating in private placements and does not affect broader market operations or retail investors.

Impact Justification

Routine debt security listing on private placement basis with no market-wide implications or regulatory changes